AMP Urges Protecting Access to Animal Models and Research Infrastructure to Ensure Framework’s Success

Washington, D.C. — February 24 — AMP issued a statement welcoming the U.S. Food and Drug Administration’s (FDA) new draft framework for individualized rare disease therapies. As policymakers work to accelerate promising new treatments, AMP underscores the importance of protecting the research models and infrastructure that make these advances possible, particularly nonhuman primates. AMP cautions that ongoing federal actions may undermine the framework’s successful implementation.

View AMP’s comments here.